Tysabri Injection
Product Images NDC 64406-008

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Tysabri (NDC 64406-008). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Biogen Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tys00 0058 01

The text seems to represent a graph or a chart showing the proportion of individuals experiencing a sustained increase in disability after receiving therapy for a certain number of weeks. The data shows that after 108 weeks of therapy, the proportion is 17%, and it remains the same after 120 weeks of therapy.*

FDA Label Image

Tys00 0058 02

FDA Label Image

Tys00 0058 03

Tysabri is a medication used for intravenous infusion only. It contains 300mg/15ml of natalizumab and must be diluted before use. The medication must not be shaken or frozen and should be protected from light. It's stored at a temperature of 28°C (36-46°F) and must be discarded if unused. The package comes with one single-dose vial of Tysabri. The medication guide should be given to each patient, and the package insert should be followed for the proper use and dosage of the medication.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.